Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Emetine is a natural alkaloid derived from the root of the ipecac plant (Uragoga ipecacuanha). It has historically been used as both an anti-protozoal agent and an emetic (to induce vomiting)[1][7]. Its primary clinical use was in the treatment of severe invasive amoebiasis, where it acts as a tissue amoebicide, concentrating mainly in the bowel wall and liver[3]. Emetine exerts its effects by binding to the 40S subunit of eukaryotic ribosomes, thereby inhibiting protein synthesis[7]. This mechanism underlies both its antiparasitic activity and its laboratory use as a protein synthesis inhibitor. Emetine also displays additional pharmacological actions including inhibition of HIF-1α expression, disruption of Wnt/β-catenin signaling pathways in cancer cells, induction of apoptosis in various tumor cell types[8], and suppression of proliferation in pulmonary arterial hypertension models via downregulation of RhoA/Rho-kinase signaling[5]. Overuse can lead to serious toxicities such as cardiomyopathy and myopathy[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Emetine.